

Index

a

- absorption, distribution, metabolism, elimination/excretion (ADME) 45, 134, 169
- acetylcholinesterase inhibitors (AChEs) 7
- acid-labile linker 131, 139
- active immunotherapeutic techniques 407
- active metal complexes 271, 276–279
- active targeted delivery
 - drug infusion pumps 351–364
 - microfabricated and nanofabricated 364–372
 - non-invasive active 372–376
- active targeting 3, 5, 8, 10, 12–13, 22, 25, 31, 46, 51–54, 59, 71, 89, 280, 301, 312, 323, 394
 - cancer cell 94
 - of liposomes 92–93
 - siRNA and mRNA lipid nanoparticles 100, 103
 - tumor endothelium 98
- active targeting strategy 52, 392
- activity-dependent neuroprotective protein (ADNP) 320
- actrapid 357
- acute myeloid leukemia (AML) 91, 128, 137, 255, 312, 313
- ADC *see* antibody drug conjugate (ADC)
- ADME *see* absorption, distribution, metabolism, elimination/excretion (ADME)
- Ado-trastuzumab emtansine (T-DM1) 128, 139
- advanced NA-based complex delivery system 232–233
- Alzheimer's disease (AD) 29, 257, 261, 263, 320, 396–398, 405, 406
 - focused on drug delivery 396–398
- AmBisome 78, 81, 90
- Amivantamab 336
- amperometry 360
- amyloid- β (A β) 261, 396, 406
- Angiopep-2 395
- antennapadia (Antp) 302
- antiangiogenic agents 52
- anti-apoptotic proteins 203
- antibody-directed enzyme prodrug therapy (ADEPT), targeted prodrugs 175–176
- antibody drug conjugate (ADC) 5, 54
 - absorption 136
 - acid-labile linker 131
 - antibody 129–130
 - bacterial infections 141
 - bioanalytical 135–136
 - Brentuximab vedotin 139
 - design 128–132
 - distribution 136
 - Enfortumab vedotin 140

- antibody drug conjugate (ADC) (*contd.*)
- Gemtuzumab Ozogamicin 137
 - glutathione disulfide linker 131
 - heterogeneity 134–135
 - inotuzumab ozogamicin 139–140
 - linker 130–132
 - mechanism of action 133
 - metabolism and elimination 136–137
 - non-cleavable linkers 131
 - non-linked drug 134
 - OBP 144
 - ONDQA 143
 - ophthalmology 141–142
 - payload 132
 - pharmacokinetic 134–137
 - polatuzumab vedotin-piiq 140
 - protease cleavable linkers 131
 - regulatory aspects for 143–144
 - resistance of 142–143
 - rheumatoid arthritis 141
 - T-DM1 139
 - trastuzumab deruxtecan 140–141
- antibody induced T-cell therapy 332
- antibody targeting 288
- anti-brain tumor effect 393, 394
- anticancer peptide nanoparticles 393
- anti-c-Met IgG 288
- antigen processing cells (APCs) 327
- antimicrobial peptides (AMPs) 203, 313, 316, 317, 322
- antioxidant enzyme 401
- antiretroviral (ARV) drugs 31, 403
- antitumor immune response 160, 161, 407, 408
- apolipoprotein E (ApoE) 397
- aptamers 23, 25, 27–28, 30, 53, 54, 97, 233, 234, 286, 301, 392, 395
- Arbaclofen placarbil 179
- arginine 302, 315, 316
- arginylglycylaspartic acid (RGD) peptide 53
- artificial pancreas 360, 361, 363
- Artificial Pancreas Device System 360
- aryl hydrocarbon receptor (AhR) 259, 261
- asthma 5, 9, 32, 321
- atherosclerosis treatment 53
- Auranofin 277, 280
- $\alpha_v\beta_3$ integrin 93, 99, 209
- b**
- bacterial infections 137, 141, 144, 323
- basic fibroblast growth factor (bFGF) 4, 375, 400, 401
- BBB *see* blood-brain barrier (BBB)
- bevacizumab 10, 99, 100, 328, 390
- B16-F10 cells 305, 306
- bFGF *see* basic fibroblast growth factor (bFGF)
- bile acid transporters 180
- bioactive agents, pharmacological properties of 275
- bioactive peptide 305
- bionic pancreas 362
- bioorthogonal coupling 288
- bispecific antibodies (bsAbs)
 - advantages of 336–337
 - disadvantages of 337
 - induced T-cell therapy 332–335
 - in T cell therapy 336
- Blinatumomab 336, 337
- blood-brain barrier (BBB) 7, 8, 29, 48, 94, 159, 170, 205, 208, 209, 263, 319, 321, 351, 389, 391–395, 397, 401–406, 410
- blood-brain tumor barrier (BBTB) 319, 391, 392
- blood vascular endothelial cells (BECs) 392
- bortezomib (BTZ) 27
- bovine lactoferricin (LfcinB) 313–314
- Box-Behnken experimental design 29
- brain cancer 205, 307–309, 319, 389, 396

- brain targeting 28, 29, 32, 53, 98, 209, 320, 389–411
- brain tumor 159, 307, 390–396, 410, 411
- breast cancer 5, 10, 12, 53, 54, 78, 91, 95–97, 128, 139, 140, 211, 233, 284, 309–312, 328, 333, 339
- Brentuximab vedotin 128, 139
- Bronchodilators 9
- bsAbs *see* bispecific antibodies (bsAbs)
- bystander effect 129, 157, 158, 160, 161, 163–165, 275, 276, 287
- C**
- Caelyx® 16, 51, 91
- cancer cell targeting
- epidermal growth receptor 95
 - folate receptor 95
 - human epidermal growth factor receptor 96–97
 - intracellular adhesion molecule-1 97–98
 - prostate-specific membrane antigen 97
 - transferrin receptor 94
- cancer immunotherapy 327, 332
- cancer indications 9–10
- cancer stem cells (CSCs) 161
- cancer therapy 137, 144, 199, 202–206, 237–238, 302–315, 330, 389, 407
- carcinoembryonic Ag (CEA) 333
- cardiac targeting peptides 207–210
- cardioprotective RNAs 207–208
- cardiosphere-derived stem cells (CDCs) 209
- cardiovascular diseases (CVDs) 8–9, 206–211, 349, 370
- CAR-T cell therapy, clinical implication of 330–331
- CD4+ T cells 327
- CD8+ T cells 327, 407
- cell death 98, 128, 133, 134, 137, 139–141, 208, 275, 284, 309, 312, 328, 336
- cell death rate 333
- cell internalization 52, 109, 201, 310
- cell penetrating peptide (CPP) 94, 231, 265, 302, 310, 315, 395
- cellular inhibitor of apoptosis protein 1 (cIAP1) 261
- central nervous system disorders (CNSDs) 319–321, 351, 389–391, 394, 396, 397, 402–409, 410
- cerebrovascular disease 400–401
- chaperones 272–276
- extracellular environment 275–276
 - metal release 276
 - protect drugs 273–275
- chaperoning 271, 273, 281, 282
- chemopreventive agents 204
- chemotherapeutic agent 10, 128, 140, 204, 272, 309, 405
- chemotherapeutic cargo 204
- chemotherapy 1, 10, 12, 34, 59, 77, 92, 140, 161, 175, 199, 210, 248, 272, 276, 306, 307, 312, 339, 352, 390, 404, 407, 408
- chimeric antigen receptor (CAR) 330
- chitosan/poly(ethylene glycol)-glycyrrhetic acid (CTS/PEG-GA) NPs 34
- chlorambucil-taurocholate 180
- chlorofluorocarbon (CFC) gas 352
- chlorotoxin (ClTx) 395
- choline acetyltransferase (ChAT)
- activity 398
- cholinesterase inhibitors 396
- choroidal neovascularization 141, 142
- classical complex-NA delivery system 229–232
- click chemistry 209

- closed loop insulin delivery systems 360–364
- CNS disorders *see* central nervous system (CNS) disorders
- cobalt(III) 274, 275, 281–283, 289
- complementary DNA (cDNA) 155
- complex-NAs based delivery systems applications 234–235
- cancer therapy 237–238
- genome editing 235, 236
- protein therapy 238–239
- connexin 43 mimetic peptide (Cx43 MP) 318
- continuous glucose monitoring (CGM) system 360
- continuous subcutaneous infusion of insulin (CSII) 355, 367
- corticosteroids 5, 9
- covalent bonding 25, 209, 302
- CRISPR associated protein 9 (CRISPR-cas9) 233, 235
- C-terminal Cend Rule (CendR) 310, 311
- Cubosomes 316, 317
- curcumin 7, 204, 209–211, 274, 393, 397, 410
- cyclosporine A (CsA) 315–316
- cytochrome C (Cyt C) 313–315, 375
- cytolytic peptides 312
- cytosine deaminase (CD) 156, 159
- cytotoxic agent 127, 137, 272, 315, 334
- cytotoxic lymphocytes 328
- cytotoxic T cells 305, 327, 328, 334
- d**
- DAMGO 321
- DART *see* dual affinity retargeting (DART)
- DaunoXome 10, 11, 29, 77, 81, 90
- deadman switch 357
- deconjugation mechanism 135
- dendritic cells 30, 51, 194, 201–203, 205, 210, 263, 335
- 2'-deoxy-2-fluoroadenosine (dFAdo) 164
- DepoFoam 77–79
- diabetes mellitus (DM) 6, 7, 354, 358, 359
- 3-diethylaminopropyl isothiocyanate (DEAP) 304–305
- 3-(3-dimethylaminopropyl)-1-ethylcarbodiimide hydrochloride (EDC) 25
- dimethyl sulfoxide (DMSO) 323
- 2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA) 79, 230
- disease-based targeting 29–31
- DNA transfection ability 229
- dock-and-lock (DNL) method 332
- dopaminergic agents 7
- DOX *see* doxorubicin (DOX)
- Doxil 4, 10, 29, 51, 77–78, 81, 82, 91, 92, 109
- doxorubicin (DOX) 10, 16, 27, 34, 35, 51, 55, 56, 58, 60, 78, 82, 85, 91, 92, 94, 96, 97, 99, 131, 139, 204, 282, 285, 393, 395
- D-penicillamine 397
- drug-antibody ratio (DAR) 132, 134–136
- drug-brain access 403
- drug delivery mechanisms 353, 405
- druggable binding sites 247
- drug infusion pumps 351–364
- drug-lipid complexes 72, 77, 78
- drug loading 60, 81, 82, 84, 85, 86, 88, 90, 202, 307, 366, 397
- drug loading techniques 80, 82, 84–85, 88
- drug-to-lipid ratio 81–82
- dry powder for inhalation (DPI) 34
- dual affinity retargeting (DART) 332, 335, 336
- dual threat metal complexes 279–280

e

- ectosomes 193
- electrochemical dissolution (oxidation) 365
- electromechanical systems 364–369
- electromigration (EM) 373, 375
- electroosmosis (EO) 373, 375
- electroporation method 198
- electrothermal activation (fusion) 365
- emulsion/solvent evaporation technique 320
- encephalomyelitis (EAE) 403, 404
- endocytosis 9, 12, 28, 88, 94, 98, 128, 130, 133, 134, 137, 158, 174, 194, 204, 227, 234, 285, 302, 310, 313, 314, 319, 402
- endogenous loading methods 198, 199
- endosomal sorting complex required for transport (ESCRT) 195
- endosome formation 194
- endothelial cell layer 319
- endothelial dysfunction 207, 400
- Enfortumab vedotin 140
- enhanced permeability and retention (EPR) effect 4, 12, 14, 15, 29, 30, 50–52, 72, 77, 89–93, 98, 109, 208, 283–286, 301, 306, 323, 391, 392
- enzymatic reaction(s) 156, 165, 299
- enzyme activation 171, 286–287
- enzyme-linked immunosorbent assay (ELISA) 135, 136, 209
- enzyme stimuli responsive 57–58
- epidermal growth factor receptor (EGFR) 93, 94, 95, 205, 259, 304, 336, 408
- epithelial cell adhesion molecule (EPCAM) 333, 337
- epithelial growth factor (EGF) 4, 396, 401
- EPR effect *see* enhanced permeability and retention (EPR) effect
- ErbB1 96
- ErbB2 96
- ErbB3 96
- ErbB4 96
- exogenous loading methods 198–199
- exosomal markers 211
- exosomal membrane 198, 199
- exosomes
 - aggregation 199
 - biogenesis of 194
 - as cancer therapeutics 199–201
 - with cardiac targeting peptides 208–210
 - cardioprotective miRNAs 208
 - for cardiovascular therapy 206–210
 - clinical evaluations 210–211
 - delivery of chemotherapeutic cargo 204
 - delivery of proteins and peptides 203
 - delivery of RNA 204–206
 - as delivery vehicles for therapeutics 195–199
 - drug delivery for cardioprotective RNAs 207–208
 - drug delivery for cardiovascular diseases 206–210
 - endogenous loading methods 198
 - evolution of 194–195
 - exogenous loading methods 198–199
 - influence of donor cells 202
 - and nano cells 233
 - for neurovascular remodeling 211
 - paracrine effects of 207
 - pathological conditions 196
 - physicochemical properties of 202
 - physiological systems and 196
 - sonication of 199
 - surface functionalization of 209
- external stimuli responsive 55
- extracellular environment
 - exploiting enzymes in 276
 - physical features of 275
- extracellular vesicles (EV) 193–199

f

- ferumoxytol (FMX) 14, 97
- Fick's laws 369
- flow cytometry 28, 304, 305, 308, 313
- fluorescein isothiocyanate (FITC) 393
- fluorescence microscopy 28
- folate-polyethylene glycol-
 - hydrophobically modified
 - dextran (F-PEG-HMD) 34
- folate receptors (FRs) 34, 93–95, 285
- folic acid 7, 53, 60, 93, 95, 204
- free energy perturbation (FEP) methods
 - 181, 182
- fusion-associated small transmembrane
 - (FAST) protein 314

g

- gas driven pumps 352–353
- GDEPT *see* gene-directed enzyme
 - prodrug therapy (GDEPT)
- geldanamycin 165
- GemRIS 354
- gemtuzumab ozogamicin 128, 137
- gene-directed enzyme prodrug therapy
 - (GDEPT)
 - high-grade gliomas (HGGs)
 - 159–161
 - molecular structures of 158
 - novel enzymes for 164–165
 - other cancers 162–164
 - targeted prodrugs 175–176
 - triple-negative breast cancer (TNBC)
 - 161–162
 - gene immunotherapy (GIT) 407
 - genetically engineered T cells 330
 - genetic alterations 330
 - gene transfer methods 330
 - genome editing 235
 - glial-determined neurotrophic factor
 - (GDNF) 399
 - glioma oncogenesis 391
 - glomerular endothelial cells (GECs)
 - 35

- glomerulonephritis (GN) 28, 35
- glucocorticosteroids (GS) 404
- glucose transporter (GLUT-1) 25, 394
- glutathione disulfide linker 131
- glycyrrhetic acid 34
- gold nanoparticles 309, 406

h

- hematoxylin and eosin (HE) staining
 - 320
 - hemoxygenase-1 401
 - hereditary transthyretin-mediated
 - (hATTR) amyloidosis 89, 100, 238
 - Herpes Simplex Virus Thymidine
 - Kinase (HSV-TK) 156, 157, 159, 160, 163
 - high-grade gliomas (HGGs) 159–161
 - high-pressure homogenization (HPH)
 - 32
 - human epidermal growth factor
 - receptor (HER) 93, 96–97
 - human umbilical vein endothelial cells
 - (HUVECs) 163, 306
 - Huperzine A (HupA) 29
 - hydrophobic tagging (HyT) 254, 263
 - hydroxamate group 273
 - 6-hydroxydopamine (6-OHDA) 399
 - [3-(hydroxymethyl)phenyl]guanidine
 - (3-HPG) 172, 173
 - hypoxia 175, 208, 272, 275, 280–282
- i**
- immune directed cancer cell death
 - 328
 - immunogenic cell death (ICD) 161
 - immunoglobulin G (IgG)-like
 - molecules 332
 - immunohistochemistry analysis 305
 - immunoliposomes (ILs) 28, 96
 - immunological diseases 263–264

- immunotherapy 10, 203, 210, 327, 328, 332, 334, 337, 339, 404, 407, 408, 410
- immunotherapy strategies, in cancer 328–329
- implantable insulin pumps 359
- implantable nanochannel device 369, 372
- indoleamine 2,3-dioxygenase (IDO) 304
- infectious diseases, targeting 30–31
- inflammatory diseases (ID) 56, 57, 95, 255, 315, 316, 402–403
- inorganic and hybrid NPs 232–233
- Inotuzumab ozogamicin 139–140
- insulin formulation 355
- insulin infusion 355, 356, 357–359, 362, 377
- insulin pumps
 - closed loop insulin delivery systems 360–364
 - diabetes and insulin product development 354–355
 - open loop insulin delivery systems 355–360
- interleukin-1 receptors (IL-1Rs) 263
- interstitium 29, 72, 89, 92, 361
- intracellular adhesion molecule-1 (ICAM-1) 93, 97–98
- intraluminal vesicle (ILV) formation 194
- Intranasal drug delivery 398, 401
- intravenous injection 73, 98, 401
- in vivo biopanning 208
- ionotropic gelation technique 34
- iontophoresis 351, 372–376
- iontophoretic assembly 373
- k**
- kidney targeting 34–35
- kinase inhibitors 95, 96, 255–257, 259, 261, 287, 406
- KRFK *see* thrombospondin-1-derived peptide (KRFK)
- Kupffer cells 12, 51
- l**
- lactoferrin (Lf) 23, 29, 203, 395, 397, 399, 400
- lanthanide oxyfluoride nanoparticle (LONp) 312, 313
- lanthanide-tagged nanoparticles (LDNp) 312
- lectins 23, 28–31, 53, 301, 398
- leukemia 91, 98, 128, 137, 183, 255, 277, 284, 312–315, 336, 337
- leukemia stem cells (LSCs) 312
- ligand-activated transcription factor 259
- ligand-anchored liposomes 70, 88
- ligand anchoring 71, 80, 83–84
- ligand-mediated targeting 5
- ligands, targeting 25–29
- lipid-based complex NA delivery system 230–231
- lipid calcium carbonate nanoparticles (LCC) 303, 304
- lipid nanocapsules (LNCs) 308, 408
- lipofectamine 205
- lipopolysaccharide (LPS) 98, 205, 263
- lipoprotein receptor-related protein (LRP) 395
- liposomes
 - active targeting 92–98
 - advantages and disadvantages of 90
 - clinical translation of 108–109
 - clinical trials with 102
 - commercial landscape 72–80
 - development and characterization of 80–88
 - drug loading techniques 84–85
 - drug-to-lipid ratio 81–82
 - ligand anchoring 83–84
 - lipids selection 80–81
 - manufacturing process 86–87

- liposomes (*contd.*)
 - passive targeting 89–92
 - pegylation 82–83
 - physico-chemical characterization 85–86
 - product stability 87–88
- liposomes ligand anchoring 84
- liquid chromatography-mass spectrometry (LC-MS) 135, 136, 163
- LiRIS 354
- liver-specific targeting 180
- liver targeting 34
- localized delivery 4–5, 108, 370
- location-based targeting 32–35
- low molecular weight protamine (LMWP) 393
- lung targeting 32, 34, 57, 321–323
- lysine rich peptides 302

- m**
- mAb *see* monoclonal antibodies (mAb)
- macromolecule/NCs 51
- magic bullet 22, 127
- magnetic field stimuli responsive 59–60
- magnetic targeting 6, 395
- major histocompatibility complex (MHC-1 and MHC-2) 203, 327
- Marqibo 80, 81, 90, 91, 109
- mastoparan (MP) 314–315, 318
- matrix metalloproteinase (MMP) 52, 57, 273, 276, 286, 287, 402
- matrix metalloproteinase-2 (MMP-2) 99, 304, 305
- MCT1-mediated transport 179
- melanoma 10, 53, 56, 203, 210, 211, 272, 304–306, 330
- melanoma associated antigens (MAGEs) 210
- mesoporous organosilica nanoparticles (MONs) 55
- mesoporous silica nanoparticles (MSN/MSNPs) 9, 55–59
- messenger RNA (mRNA) 85, 100–102, 108, 109, 155, 195, 197, 205, 221, 231, 330, 399 *see also* nucleic acids (NAs)
- delivery of 227
- lipid nanoparticles 100–102
- metal complexes
 - active 276–279
 - caging of fluorophore 282
 - chaperones 272–276
 - chemical and physical environment 280–284
 - dual threat 279–280
 - enzyme activation 286–287
 - stability of 274
 - transporters 284–286
- metastatic castration-resistant prostate cancer (mCRPC) 163, 164, 255, 257
- microchip-based MEMS 364–366
- micro-chip style models 392
- microdialysis 321
- micro drop master jet (MPV) 322
- microelectromechanical systems (MEMS) 351, 364–369
 - effort to close loop 368–369
 - microchip-based 364–366
 - pump-based 366–368
- micro RNAs (miRNA) 195, 197, 198, 202, 204–208, 211, 221, 230, 234
- microvesicles 193
- Mill Hill infuser 355, 358
- mitochondrial targeting 287–288
- molecular glue 265
- monocarboxylate transporter type 1 179–180
- monoclonal antibodies (mAb) 10, 53, 54, 81, 95–99, 127–132, 137, 139–141, 143, 144, 175, 313, 328, 375, 408

- mononuclear phagocytic system (MPS)
cells 12, 31, 81, 89, 91
- morphine sulfate 352, 353
- Morris Water Maze (MWM) 320
- mRNA *see* messenger RNA (mRNA)
- mucoadhesive neuronanoemulsion
(mNNE) 32, 33
- multiple sclerosis (MS) 396, 403–404
- multivesicular body (MVB) formation
194
- multivesicular endosomes (MVE)
193–195
- murine microvascular endothelium cell
lines (BMECs) 395, 402
- Mycobacterium tuberculosis* (MTB) 9,
30, 322
- myocardial ischemia-reperfusion (IR)
8, 209
- n**
- N-acetylneuraminic acid 53
- NA-CRISPR-cas9 237
- nanocarriers 6, 12, 13, 15, 23, 26
active targeting approaches 52–54
clinical investigation scenario 49
electrostatic interaction or Van der
Waals forces 302
passive targeting approaches 50–52
stimuli responsive targeted 54–60
in targeted drug delivery 45–49
- nanochannel drug delivery system
(nDS) 370
- nano-electromechanical systems
(NEMS) 351, 364, 369
- nanoliposomal irinotecan (nal-IRI)
14, 97
- nanomedicines 7, 11, 22, 29, 38
in targeted drug delivery 45–49,
103, 389, 391, 407, 410
- nanomicelles 34
- nano pharmaceuticals carriers 391,
394
- natural killer (NK) cells 210, 305, 328,
329, 333, 335, 336
- naturally occurring T-cells (TILs)
329–330, 337
- nerve growth factor (NGF) 7, 401
- neuro-AIDS 403
- neurodegenerative diseases/disorders
238, 255, 261–263, 389, 396–405,
410, 411
- neuroinvasive viruses 402
- neurological diseases 7–8, 319
- neuronanoemulsions (NNEs) 32
- neuropilin-1 (Nrp-1) receptors 310,
311
- N-(2-hydroxypropyl)methacrylamide
(HPMA) 52
- N-hydroxysuccinimide (NHS) 25
- nitric oxide (NO) 52, 273
- NLG919 304, 305
- N-methyl-D-aspartate (NMDA) 396
- non-cleavable linkers 131
- non-IgG-like antibodies 332
- nonmammalian enzymes 156, 176
- non-self DNA 155
- non-small cell lung cancer (NSCLC)
cell line 34, 95, 272
- non-stealth liposome 91
- nuclear localization signals (NLS) 231
- nucleic acids (NAs)
administrations of 222
advanced NA-based complex delivery
system 232–233
classical complex-NA delivery system
229–232
complex delivery system 226
exosomes and nano cells 233
inorganic and hybrid NPs 232–233
lipid-based complex NA delivery
system 230–231
mode of action 224
peptide-based complex NA delivery
system 231–232
physical properties and 224

- nucleic acids (NAs) (*contd.*)
- polymer-based complex NA delivery system 229–230
 - self-assembled NA nanostructures 233
 - siRNA 228
- nucleoside-modified mRNA 101, 235
- nutrient uptake pathways 276, 284
- nViSTA device 371
- O**
- odorranalectin 28, 398, 399
- Office of Biological Products (OBP) 143, 144
- Office of New Drug Quality Assessment (ONDQA) 143, 144
- oncogenes 238, 328, 407
- Onivyde 92
- Onpattro (Patisiran) 100, 239
- open loop insulin delivery systems 355–360
- ophthalmology 80, 109, 141–142, 144
- opsonization 4, 51, 70
- oseltamivir 177
- osmotic pumps 351, 353–354
- overexpress specific proteins 198
- OX7-coupled immunoliposomes (OX7-IL) 35
- OX26 TfR 399
- P**
- pancreatic cancer 306
- parallel artificial membrane permeability assay (PAMPA) 254
- Parkinson's disease (PD) 8, 32, 261, 352
- focused on drug delivery 399–400
- passive targeting 22
- approaches 50–52
 - EPR effect 4, 12, 50, 52
 - of liposomes 89–92
 - localized delivery 4–5
 - reticulo-endothelial system (RES) system 4
- Patisiran 100, 234, 239
- PEGylated liposome 8, 31, 51, 70, 71
- PEGylated nanoformulations 201
- Pegylation 51, 70, 71, 77, 80, 82–83
- peptide-based complex NA delivery system 231–232
- peptide targeting
- brain delivery of 319–321
 - lung delivery of 321–323
 - ocular delivery of 317–319
 - topical delivery of 315–317
- peptide transporter 1 (PEPT1) 172, 173, 176–179
- perfluorooctyl bromide (PFOB) 312
- peristaltic pumps 351–352, 355, 357
- permeability transition pore (PTP) 314
- P450 gene transfer (P450 GDEPT) 176
- pharmacokinetics 10, 32, 35, 38, 72, 81, 88, 90, 92, 108, 130, 134–137, 144, 169, 170, 183, 261, 265, 299, 312, 321, 349, 355, 366, 370, 395
- pH-based targeting 282–283
- phosphate buffered saline (PBS) 323
- phosphatidylserine 99, 195
- phospholipase A2-mediated prodrug activation 173–174
- photo-immunoconjugates (PIC) delivery 408–409
- photoimmunotherapy (PIT) 408–409
- pH stimuli responsive 56–57
- physical targeting
- magnetic field 6
 - ultrasound 6
- physico-chemical characterization 80, 85–86
- physicochemical drug properties 170
- PLA nanocapsules 31
- platinum anticancer agents 274, 277, 279, 288
- Polatuzumab vedotin-piiq 140
- poly (ϵ -caprolactone) (PCL) 306, 307

- poly(ethylene imine) (PEI) 9, 229, 230
poly(lactic-co-glycolic acid) (PLGA) 7, 8, 28–30, 54, 59, 408
polyamidoamine (PAMAM) dendrimer 395
polydispersity index (PDI) 87, 316, 322
polydopamine nanoparticles (PDA NPs) 27
polyethylene glycol (PEG) 28, 51, 82, 92, 97, 230, 261, 301, 306, 365, 400
poly-L-lysine (PLL) 229, 231, 232
polymer-based complex NA delivery system 229–230
Polymer Brush 82
polymeric NCs 45, 53, 55, 58
polyubiquitinylation 248, 254, 261, 265
portable insulin dosage-regulating apparatus (PIDRA) 357
prodrug activation step 176
prodrug approach 169–180, 182, 184
product stability 80, 87–88
programmed cell death-ligand 1 (PD-L1) 304, 337, 407
prostate cancer (PCa) 5, 58, 95, 97, 163, 164, 183, 204, 210, 211, 284, 286, 354
prostate specific antigen (PSA) 97, 163, 286, 287
prostate specific membrane antigen (PSMA) 93, 97, 284, 286
PROTACs *see* proteolysis targeting chimeras (PROTACs)
protease cleavable linkers 131, 139, 140
protein degradation 247, 254, 264, 265
protein electrotransport 375
protein kinase N3 (PKN3) 237
protein misfolding 254
protein of interest (POI) 247
 mechanism 248
protein-protein interactions 247
proteins overexpression 203
protein therapy 234, 235, 238–239
protein transduction domains (PTD) 302
proteolysis targeting chimeras (PROTACs)
 cancer 255–261
 design of 252–254
 development 265
 immunological diseases 263–264
 neurodegenerative disorders 261–263
 pharmacokinetic-pharmacodynamic evaluation 265
 physicochemical properties of 254
 therapeutic applications of 254–264
 viral infections 264
protooncogenes 328
pump-based MEMS 366–368
purine nucleoside phosphorylase (PNP) 156, 159
- q**
quality by design (QbD) 86, 87
quantum mechanics/molecular mechanics (QM/MM) 181
- r**
reactive oxygen species (ROS) 8, 401
receptor mediated targeting 57
recombinant adeno-associated virus (rAAV) 165
redox stimuli responsive 55–56
relapsed or refractory large B-cell NHL (RR DLBCL) 339
respiratory diseases 9, 32, 349
reticuloendothelial system (RES) 4, 22, 51, 70, 301, 329
RGD peptide *see* arginylglycylaspartic acid (RGD) peptide
rheumatoid arthritis 57, 95, 137, 141, 277, 286, 370

- ribonucleoprotein complexes (RNPs) 235
 - RNA delivery 100, 204, 206
 - RNase degradation 198
 - ropinirole-dextran sulfate (ROPI-DS) 32
- S**
- secreted protein acidic and rich in cysteine (SPARC) 163
 - self-assembled NA nanostructures 233
 - sensor augmented therapy 361
 - serum hPTH(1-34) 375
 - single-photon emission computed tomography (SPECT) 34
 - siRNA *see* small interference RNA (siRNA)
 - site-specific drug delivery 46, 171, 182, 193
 - small angle X-ray scattering (SAXS) technique 85
 - small interference RNA (siRNA) 30, 54, 55, 60, 79, 89, 100–102, 108, 109, 197–199, 204, 205, 208, 211, 221–231
 - delivery of 226
 - lipid nanoparticles 100, 101
 - small-molecule agents 247, 262, 265
 - sodium-dependent multivitamin transporter (SMVT) 179, 183
 - Solanum tuberosum* lectin (STL) 28
 - solid lipid nanoparticles (SLN) 30, 397
 - somatostatin (SST) 306
 - sonication-induced deformation 199
 - stable NA-lipid particles (SNALPs) 237
 - standard peptide coupling methods 279
 - STAT3/NF- κ B signaling pathway 161
 - stimuli responsive targeted NCs
 - enzyme 57–58
 - magnetic field 59–60
 - pH 56–57
 - redox 55–56
 - temperature 58–59
 - ultrasound 59
 - stratum corneum (SC) 315
 - subcutaneous infusion 351, 355, 367
 - suicide gene therapy 155–165, 175
 - systematic evolution of ligands by
 - exponential enrichment (SELEX) process 53–54
- t**
- targeted delivery
 - Alzheimer's diseases 396–398
 - brain tumor 390–396
 - cerebrovascular diseases 400–401
 - chemotherapy 408
 - CNS disorders 404–409
 - gene immunotherapy 407
 - immunotherapy 407
 - inflammatory diseases (ID) 402–403
 - multiple sclerosis 403–404
 - neuro-AIDS 403
 - neurodegenerative diseases 396–404
 - Parkinson's diseases 399–400
 - photoimmunotherapy 408–410
 - Tau therapy 405–407
 - targeted drug delivery systems 2, 3
 - active 5, 12, 13
 - applications of 6–10
 - approaches 29–35
 - bioavailability (BA) 2
 - biological effects 1
 - brain 32
 - clinical perspectives 35–38
 - FDA-approved nanotechnology 36
 - infectious diseases 30–31
 - kidney 34–35
 - level of 24
 - ligand 25–29
 - ligand-mediated 5
 - liposomes 69
 - liver 34

- location-based 32
- lung 32, 34
- passive 4–5, 12
- physical 5–6
- products 10–11
- regulatory aspects 35–38
- scale-up and challenges 13–14
- stages of clinical trials 37
- therapeutic index 2
- tumor 29–30
- targeted prodrugs
 - antibody, gene and virus-directed 175–176
 - bile acid transporters 180
 - classic vs. modern approach 170–171
 - clinical applications 183
 - computational approaches in 181–182
 - modern approach 171–180
 - monocarboxylate transporter type 1 179–180
 - peptide transporter 1 (PEPT1) 177–179
 - phospholipase A2-mediated prodrug activation 173–174
 - valacyclovirase-mediated prodrug activation 172–173
- targeting ligands 25
 - antibodies as 28
 - aptamers as 27–28
 - lactoferrins as 29
 - lectins as 28
 - small molecules as 25, 27
- targeting strategies, chemical and physical environment 280–284
- tauopathy mechanism 406
- tau therapy 405–407
- T cell-activating antibodies (TABs) 332, 333, 337
- T-cell, clinical implication of 330–331
- T cell proliferation 304, 334
- T cell therapy 329
- antibody induced 332
- bispecific antibodies in 336–337
- BsAbs induced 332–335
- clinically approved 337–339
- Triomab antibodies in 335
- T-DM1 *see* Ado-trastuzumab emtansine (T-DM1)
- temozolomide (TMZ) 34, 390
- temperature stimuli responsive 58–59
- TGNYKALHPHNG 398
- theranostic agent 28, 69, 309
- therapeutic peptides
 - assembling nanoparticles 305
 - brain cancer 307–309
 - breast cancer 309–312
 - leukemia 312–315
 - in lung cancer 303–304
 - melanoma 304–306
 - pancreatic cancer 306–307
- thermosensitive nanocarriers 58
- thrombolytic drugs 59
- thrombospondin-1-derived peptide (KRFK) 318
- tight intersections (TJs) 391, 403
- tirapazamine 281
- tissue plasminogen activator (t-PA) 59
- TLR9 agonist 408
- tLyP-1 peptide 311
- toll-like receptors (TLRs) 263
- transactivator of transcription peptide (TAT) 302, 395
- transactive response (TAR)
 - DNA-binding protein (TDP-43) 263
- transferrin receptor 93–94, 392
- Trastuzumab deruxtecan 140–141
- triomab antibodies 335
- triple-negative breast cancer (TNBC) 98, 161–162, 255
- tumor associated antigens (TAA) 10, 175, 335, 337
- tumor-derived exosomes 201
- tumor endothelium targeting

- tumor endothelium targeting (*contd.*)
 phosphatidylserine 99
 vascular endothelial growth factor
 98–99
 $\alpha_v\beta_3$ integrin 99
- tumor necrosis factor-alpha (TNF- α)
 9, 30, 56, 57, 97, 335, 337, 408
- tumor-penetrating peptide 57, 308,
 309
- tumor targeting 29–30, 50, 53, 57, 58,
 95, 108, 203, 307, 395
- tumor vasculature 4, 30, 59, 77
- tyrosine hydroxylase (TH) 399
- U**
- ubiquitin-proteasomal system (UPS)
 248, 254, 261
- Ulex europaeus* agglutinin I (UEA-I)
 28
- ultrasound stimuli responsive 59
- ultrasound targeting 6
- unmet needs 8, 22, 109, 271–289, 351,
 374
- V**
- valacyclovirase-mediated prodrug
 activation 172–173
- vascular endothelial growth factor
 (VEGF) 4, 10, 93, 98–99, 161,
 205, 401
- vasoactive intestinal peptide-loaded
 liposomes (VLL) 322
- viral infections 159, 262, 264
- virus-directed enzyme prodrug therapy
 (VDEPT) 175–176
- Visudyne 78, 91
- W**
- wheat germ agglutinin (WGA) 28,
 397, 398
- withaferin A 204
- X**
- xenograft model 58, 255, 257, 311
- xenografts 28, 175, 202, 287, 312,
 395
- xeno nucleic acids 221
- X-ray photoelectron spectroscopy (XPS)
 320
- Z**
- ziconotide 352
- Zolmitriptan 373, 374

